Concepedia

Charles L. Bisgaier

CL

Statistics

Publications

48

Citations

5.1K

H-Index

29

Active since

1979

Affiliations

Esperion Therapeutics (United States)(Current)

University of Michigan

Pfizer (United States)

Rappaport Family Institute for Research in the Medical Sciences

Alchem Laboratories (United States)

Charles L. Bisgaier is an author at Esperion Therapeutics (United States) specializing in life sciences, biochemistry, and pharmacology.

Publications per year

1979–2023

48

Publications

48

Human serum paraoxonase (PON 1) is inactivated by oxidized low density lipoprotein and preserved by antioxidants

Michael Aviram, Mira Rosenblat, Scott S. Billecke et al. · Free Radical Biology and Medicine · 1999 · 600 citations

, , +7

Acid sphingomyelinase deficient mice: a model of types A and B Niemann–Pick disease

Kenichi Horinouchi, Shai Erlich, Daniel P. Perl et al. · Nature Genetics · 1995 · 477 citations

, , +15

Paraoxonase Active Site Required for Protection Against LDL Oxidation Involves Its Free Sulfhydryl Group and Is Different From That Required for Its Arylesterase/Paraoxonase Activities

Michael Aviram, Scott S. Billecke, Robert C. Sorenson et al. · Arteriosclerosis Thrombosis and Vascular Biology · 1998 · 454 citations · Full text

, , +15

High-Dose Recombinant Apolipoprotein A-I <sub>Milano</sub> Mobilizes Tissue Cholesterol and Rapidly Reduces Plaque Lipid and Macrophage Content in Apolipoprotein E–Deficient Mice

Prediman K. Shah, Juliana Yano, Odette S. Reyes et al. · Circulation · 2001 · 378 citations · Full text

, , +17

Human Serum Paraoxonase/Arylesterase’s Retained Hydrophobic<i>N</i>-Terminal Leader Sequence Associates With HDLs by Binding Phospholipids

Robert C. Sorenson, Charles L. Bisgaier, Cary Hsu et al. · Arteriosclerosis Thrombosis and Vascular Biology · 1999 · 326 citations · Full text

, , +14

1–5 of 48